Synergistic antitumor activity of regorafenib and lapatinib in preclinical models of human colorectal cancer

被引：30
|
作者：
Zhang, Wen-Ji [1 ,2 ]
Li, Yong [3 ]
Wei, Meng-Ning [1 ,2 ]
Chen, Yao [1 ,2 ]
Qiu, Jian-Ge [1 ,2 ]
Jiang, Qi-Wei [1 ,2 ]
Yang, Yang [1 ,2 ]
Zheng, Di-Wei [1 ,2 ]
Qin, Wu-Ming [1 ,2 ]
Huang, Jia-Rong [1 ,2 ]
Wang, Kun [1 ,2 ]
Zhang, Wen-Juan [4 ]
Wang, Yi-Jun [5 ]
Yang, Dong-Hua [5 ]
Chen, Zhe-Sheng [5 ,6 ]
Shi, Zhi [1 ,2 ]
机构：
[1] Jinan Univ, Dept Cell Biol, Guangzhou 510632, Guangdong, Peoples R China
[2] Jinan Univ, Inst Biomed, Natl Engn Res Ctr Genet Med, Guangdong Prov Key Lab Bioengn Med,Coll Life Sci, Guangzhou 510632, Guangdong, Peoples R China
[3] Guangdong Acad Med Sci, Guangdong Gen Hosp, Dept Gastrointestinal Surg & Gen Surg, Guangzhou 510080, Guangdong, Peoples R China
[4] Jinan Univ, Dept Prevent Med, Coll Med, Guangzhou 510632, Guangdong, Peoples R China
[5] St Johns Univ, Dept Pharmaceut Sci, Coll Pharm & Hlth Sci, Queens, NY 11439 USA
[6] Jinan Univ, Coll Pharm, Guangdong Prov Key Lab Pharmacodynam Constituents, Guangzhou 510632, Guangdong, Peoples R China
来源：
CANCER LETTERS | 2017年 / 386卷
基金：
中国国家自然科学基金;
关键词：
Regorafenib; Lapatinib; Targeted therapy; Combination chemotherapy; Colorectal cancer; MULTIDRUG-RESISTANCE; BREAST-CANCER; DRUG-SENSITIVITY; PHASE-3; TRIAL; TUMOR-GROWTH; COLON-CANCER; INHIBITOR; CELLS; COMBINATION; MULTICENTER;
D O I：
10.1016/j.canlet.2016.11.011
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Regorafenib significantly prolongs overall survival in patients with metastatic colorectal cancer (mCRC), but the overall clinical efficacy of regorafenib remains quite limited. Combination chemotherapy is a potentially promising approach to enhance anticancer activity, overcome drug resistance, and improve disease-free and overall survival. The current study investigates the antitumor activity of regorafenib in combination with lapatinib in preclinical models of human CRC. Our results show improved antitumor efficacy when regorafenib is combined with lapatinib both in vitro and in vivo. Furthermore, pharmacokinetic analyses revealed that regorafenib and lapatinib do not influence on each plasma concentration. The finding that regorafenib in combination with lapatinib have synergistic activity warrants further clinical investigation of this beneficial combination as a potential treatment strategy for CRC patients. (C) 2016 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码：100 / 109
页数：10
相关论文
共 50 条
  • [31] Antitumor activity of sorafenib in osteosarcoma (OS) preclinical models
    Pignochino, Y.
    Grignani, G.
    Cavalloni, G.
    Motta, M.
    Bruno, S.
    Camussi, G.
    Ferrari, S.
    Picci, P.
    Berger, M.
    Aglietta, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [32] Synergistic antitumor effect of 5-fluorouracil in combination with parthenolide in human colorectal cancer
    Kim, Se-Lim
    Kim, Seong Hun
    Kieu Thi Thu Trang
    Kim, In Hee
    Lee, Seung-Ok
    Lee, Soo Teik
    Kim, Dae Ghon
    Kang, Sang-Beom
    Kim, Sang-Wook
    CANCER LETTERS, 2013, 335 (02) : 479 - 486
  • [33] Antisecretive and Antitumor Activity of Abiraterone Acetate in Human Adrenocortical Cancer: A Preclinical Study
    Fiorentini, Chiara
    Fragni, Martina
    Perego, Paola
    Vezzoli, Sara
    Bonini, Sara A.
    Tortoreto, Monica
    Galli, Diego
    Claps, Melanie
    Tiberio, Guido A.
    Terzolo, Massimo
    Missale, Cristina
    Memo, Maurizio
    Procopio, Giuseppe
    Zaffaroni, Nadia
    Berruti, Alfredo
    Sigala, Sandra
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2016, 101 (12): : 4594 - 4602
  • [34] Improved Antitumor Activity of the Fluoropyrimidine Polymer CF10 in Preclinical Colorectal Cancer Models through Distinct Mechanistic and Pharmacologic Properties
    Gmeiner, William H.
    Dominijanni, Anthony
    Haber, Alex O.
    Ghiraldeli, Lais P.
    Caudell, David L.
    D'Agostino, Ralph, Jr.
    Pasche, Boris C.
    Smith, Thomas L.
    Deng, Zhiyong
    Kiren, Sezgin
    Mani, Chinnadurai
    Palle, Komaraiah
    Brody, Jonathan R.
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (03) : 553 - 563
  • [35] Evaluation of the Antitumor Activity of Dacomitinib in Models of Human Bladder Cancer
    Grivas, Petros D.
    Day, Kathleen C.
    Karatsinides, Andreas
    Paul, Alyssa
    Shakir, Nazia
    Owainati, Iya
    Liebert, Monica
    Kunju, Lakshmi P.
    Thomas, Dafydd
    Hussain, Maha
    Day, Mark L.
    MOLECULAR MEDICINE, 2013, 19 : 367 - 376
  • [36] Evaluation of the Antitumor Activity of Dacomitinib in Models of Human Bladder Cancer
    Petros D. Grivas
    Kathleen C. Day
    Andreas Karatsinides
    Alyssa Paul
    Nazia Shakir
    Iya Owainati
    Monica Liebert
    Lakshmi P. Kunju
    Dafydd Thomas
    Maha Hussain
    Mark L. Day
    Molecular Medicine, 2013, 19 : 367 - 376
  • [37] Synergistic activity between niraparib and chemotherapy in colorectal cancer: Molecular determinants from a preclinical model
    Vitiello, P. P.
    Ciardiello, D.
    Cardone, C.
    Martini, G.
    Belli, V.
    Borrelli, C.
    Poliero, L.
    Arrichiello, G.
    De Falco, V.
    Giunta, E. F.
    Terminiello, M.
    Troiani, T.
    Ciardiello, F.
    Martinelli, E.
    ANNALS OF ONCOLOGY, 2019, 30
  • [38] Synergistic antitumor activity of troxacitabine and camptothecin in selected human cancer cell lines
    Kim, TE
    Park, SY
    Hsu, CH
    Dutschman, GE
    Cheng, YC
    MOLECULAR PHARMACOLOGY, 2004, 66 (02) : 285 - 292
  • [39] Synergistic Antitumor Activity of Lapatinib and Retinoids on a Novel Subtype of Breast Cancer With Co-amplification of ERBB2 and RARA
    Paroni, G.
    Fratelli, M.
    Flora, M.
    Zanetti, A.
    Centritto, F.
    Affatato, R.
    Ubezio, P.
    Terao, M.
    Gardini, G.
    Garattini, E.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : S255 - S256
  • [40] Preclinical antitumor activity of the MEK inhibitor R05068760 in human tumor xenograft models
    Brian, Higgins
    Kolinsky, Kenneth
    Daouti, Sherif
    Rizzo, Christine
    Wang, Huisheng
    Huby, Nicholas
    Niu, Huifeng
    Packman, Kathryn
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
12345